<DOC>
	<DOCNO>NCT00084565</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel , topotecan , estramustine , work different way stop tumor cell divide stop grow die . Giving one chemotherapy drug may kill tumor cell . PURPOSE : This phase II trial study well give paclitaxel , topotecan , estramustine together work treat patient metastatic hormone therapy-refractory prostate cancer .</brief_summary>
	<brief_title>Paclitaxel , Topotecan , Estramustine Treating Patients With Metastatic Hormone-Refractory Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine objective response rate patient metastatic hormone-refractory prostate cancer treat paclitaxel , topotecan , estramustine . - Determine progression-free overall survival patient treat regimen . - Determine toxic effect regimen patient . - Determine pharmacokinetics regimen patient . Secondary - Determine frequency number circulate tumor cell patient treatment regimen disease progression . - Determine microtubule morphology , β-tubulin isotype pattern , apoptotic marker , metaphase chromosome alignment circulate tumor cell patient treatment regimen disease progression . OUTLINE : Patients receive paclitaxel IV 1 hour day 1 , 8 , 15 ; topotecan IV 30 minute day 2 , 9 , 16 ; oral estramustine twice daily day 1 2 course 1 day 0-2 , 7-9 , 14-16 subsequent course . Courses repeat every 28 day absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 18-38 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate gland Progressive metastatic disease ( e.g. , bone , pelvic mass , lymph node , liver lung metastasis ) Radiologic evidence hydronephrosis alone dose constitute metastatic disease Failed prior primary hormonal therapy ( e.g. , estrogen therapy , luteinizing hormonereleasing hormone blocker flutamide ) bilateral orchiectomy Patients previously treat flutamide bicalutamide must evidence disease progression i.e. , increase ProstateSpecific Antigen ( PSA ) PSA level ≥ 10 ng/mL bone metastasis present ( i.e. , lack measurable soft tissue disease ) No elevated serum acid phosphatase PSA level evidence disease No carcinomatous meningitis brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status Eastern Cooperative Oncology Group ( ECOG ) 02 Life expectancy At least 12 week Hematopoietic White Blood Cell ( WBC ) ≥ 4,000/mm^3 OR Granulocyte count ≥ 2,000/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Serum GlutamicOxaloacetic Transaminase ( SGOT ) Serum GlutamicPyruvic Transaminase ( SGPT ) ≤ 2 time normal Bilirubin ≤ 1.5 mg/dL Renal Creatinine ≤ 2.0 mg/dL OR Creatinine clearance ≥ 50 mL/min Cardiovascular History deep venous thrombosis allow provided patient maintain therapeutic anticoagulation therapy No active angina pectoris No New York Heart Association class IIIV heart disease No myocardial infarction within past 6 month No thrombosis within past 3 month Other Fertile patient must use effective contraception 3 month study participation No active infection No concurrent serious medical illness would preclude study participation No malignancy within past 3 year except curatively treat basal cell squamous cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy Endocrine therapy See Disease Characteristics At least 4 week since prior flutamide At least 8 week since prior bicalutamide Radiotherapy More 4 week since prior radiotherapy No prior strontium chloride Sr 89 samarium Sm 153 lexidronam pentasodium Surgery See Disease Characteristics Other Recovered prior therapy No prior cytotoxic therapy prostate cancer No concurrent milk , milk product , antacid , calciumcontaining drug , food estramustine administration</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>adenocarcinoma prostate</keyword>
</DOC>